Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults

Pediatr Infect Dis J. 2016 Dec;35(12):1333-1335. doi: 10.1097/INF.0000000000001320.

Abstract

HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

Trial registration: ClinicalTrials.gov NCT00977756.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Atazanavir Sulfate / administration & dosage
  • Atazanavir Sulfate / blood
  • Atazanavir Sulfate / pharmacokinetics*
  • Atazanavir Sulfate / therapeutic use
  • Child
  • HIV Infections / drug therapy*
  • Humans
  • Prospective Studies
  • Young Adult

Substances

  • Atazanavir Sulfate

Associated data

  • ClinicalTrials.gov/NCT00977756